PCOS: Understanding The Silent Impact On Women’s Health
1. Aidarbek kyzy Aidanek
2. Cathalin Salaman
Anandhavelu Sorna
Murugavel Elakkiya
(1. Lecturer, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.
2. Students, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
ABSTRACT
Polycystic ovary syndrome, or PCOS, is an endocrine disorder in females in the reproductive age group. It has major reproductive, metabolic, and psychological implications. It is characterized by hyperandrogenism, anovulation, and polycystic ovarian morphology. These are caused by complex hormonal and metabolic abnormalities. In patients with PCOS, various symptoms are seen. These include menstrual irregularities, infertility, hirsutism, acne, and obesity. In the long term, patients are at increased risk for insulin resistance, type 2 diabetes, cardiovascular disease, and endometrial hyperplasia. The cause of PCOS Is complex and includes genetic predisposition, environmental factors, and lifestyle. The criteria for diagnosing PCOS are the Rotterdam criteria. The treatment includes symptom-based management. This includes lifestyle modifications, medication, and in some cases, surgery. Recent advances in the management and treatment of PCOS have revealed the role of the gut microbiome, genetic markers, and new treatments. Although it is not life-threatening, it does affect the quality of life and long-term prognosis. This review gives an overview of the epidemiology, symptoms, treatment options, and advances in the management and treatment of PCOS.
Keywords: Polycystic ovary syndrome (PCOS), Hyperandrogenism, Anovulation, Infertility, Insulin resistance, Metabolic syndrome.
INTRODUCTION
“The Whisper of Hormones, The Shout of Health: PCOS”
Polycystic ovary syndrome (PCOS) is a very common, heterogeneous, and one of the most common endocrine disorders among women of reproductive age. It is characterized by a variety of reproductive, metabolic, and psychological abnormalities, and is a leading cause of menstrual irregularities, infertility, hirsutism, acne, and obesity, and is also known to increase the risk of insulin resistance, type 2 diabetes, cardiovascular diseases, and endometrial hyperplasia. The etiology of PCOS Is complex and multifactorial, and is influenced by genetic predisposition, environmental factors, and lifestyle. It is diagnosed by standardized criteria such as the Rotterdam criteria, as there is no single diagnostic marker for this condition. There is new research and evidence about the management of this condition, and this review aims to highlight a concise overview of this condition, its clinical presentation, and its management strategies.
OBJECTIVE
1) To provide a comprehensive overview of polycystic ovary syndrome (PCOS), including its causes, risk factors, clinical features, diagnosis, treatment, prevention, and recent management advances.
2) A literature review was conducted using online scholarly databases, including peer-reviewed journals and articles by leading experts in endocrinology and reproductive health.
METHOD OF STUDY
DEFINITION:
Polycystic ovary syndrome, or PCOS, is a hormonal disorder in which androgen levels are higher than normal, causing irregular menstrual periods, abnormal ovulation, and infertility in females, as well as excessive hair growth and acne.
ETIOLOGY (Causes):
1) Genetic Predisposition
· Family history plays a role in PCOS development.
· Specific gene variations affect hormone levels, ovarian function, and metabolism.
2) Hormonal Imbalance
· Hyperandrogenism: Excessive male hormones affect ovulation and follicular development.
· Insulin Resistance & Hyperinsulinemia: Poor insulin response causes increased androgen production and ovulation problems.
· Hypothalamic-Pituitary-Ovarian Dysregulation: Abnormal signaling pathways increase luteinizing hormone, which stimulates androgen production.
3) Chronic Inflammation
· Inflammation causes hormonal imbalance, which may lead to metabolic complications.
4) Environmental & Lifestyle Factors
· Obesity, a high-calorie diet, and a sedentary lifestyle may exacerbate insulin resistance and hormonal imbalance.
· Exposure to environmental toxins such as (eg: BPA ) may affect hormone signaling pathways.
· Gut microbiota imbalance may contribute to metabolic complications.
5) Developmental & Epigenetic Factors
· Prenatal androgen exposure may predispose to PCOS.
· Epigenetic factors may affect gene expression, which may increase PCOS risk.
PATHOPHYSIOLOGY:
1) Neuroendocrine Dysregulation – Abnormal GnRH pulsatility causes elevated LH levels compared to FSH, increasing androgens and decreasing follicular maturation.
2) Hyperandrogenism – Increased androgens from the ovary and adrenals impair follicular development, cause anovulation, and manifest as clinical symptoms.
3) Insulin Resistance – Hyperinsulinemia increases androgen production from the ovary and decreases SHBG, increasing androgens.
4) Role of Anti-Müllerian Hormone (AMH) –Elevated AMH alters follicular dynamics and contributes to ovulatory dysfunction in PCOS.
5) Vicious Cycle – Hyperandrogenism and hyperinsulinemia reinforce each other, perpetuating hormonal and ovulatory disturbances.
6) Role of Genetic and Epigenetic Factors – Genetic and epigenetic factors are responsible for the etiology and severity of PCOS.
7) Role of Metabolic and Tissue Factors – The liver, muscles, and adipose tissue play significant roles in glucose and lipid metabolism, and obesity is linked to insulin resistance and hormonal imbalance.
SYMPTOMS
1) Menstrual and Ovulatory Dysfunction:
· Irregular, infrequent, or absent menstrual cycles (oligomenorrhea/ amenorrhea).
· Anovulation leading to infertility.
2) Hyperandrogenic signs
· Hirsutism, acne, oily skin, and androgenic alopecia.
· Biochemical Hyperandrogenism may occur without visible symptoms.
3) Metabolic Features
· Insulin resistance and hyperinsulinemia.
· Abdominal obesity, weight gain, dysglycemia, and dyslipidemia.
· Increased risk of type 2 diabetes and metabolic syndrome.
4) Dermatologic Features
· Acanthosis nigricans, seborrhea, and persistent acne.
· Reflect underlying insulin resistance and androgen excess.
5) Psychological Impact
· Anxiety, depression, reduced self- esteem, and body image concerns.
6) Long – Term Health Risks
· Cardiovascular disease, hypertension, and sleep disorders.
· Endometrial hyperplasia and cancer risk due to chronic anovulation.
· Increased prevalence of nonalcoholic fatty liver disease.
RISK FACTORS
· Genetic predisposition: Family history increases risk.
· Insulin resistance and hyperinsulinemia: Drives excess androgen production.
· Obesity and Visceral fat: worsens metabolic and hormonal imbalance.
· Hormonal imbalance: Elevated androgens disrupt ovulation.
· Lifestyle Factors: sedentary habits, poor diet , stress.
· Ethnicity : South Asian women show higher prevalence and metabolic risks(due to higher insulin resistance and central obesity tendency).
Its diagnosis is based on a combination of clinical, biochemical, and imaging parameters. There is no single test or investigation to confirm a diagnosis of PCOS, and a standardized approach is followed to diagnose this condition.
DIAGNOSTIC CRITERIA:
The most frequently applied criteria to diagnose Polycystic Ovary Syndrome (PCOS) are the Rotterdam Criteria (2003). This criteria states that a diagnosis of PCOS is made if any two of the following three criteria are satisfied:
1. Ovulatory Dysfunction
· Oligomenorrhea (menstrual cycles >35 days).
· Amenorrhea (menstrual irregularity or absence of menstruation for >3 months).
· Irregular or unpredictable menstrual cycles.
· Chronic anovulation.
2. Hyperandrogenism
Either clinical or biochemical evidence of this condition is required to make a diagnosis of Polycystic Ovary Syndrome (PCOS).
· Clinical evidence of Hyperandrogenism.
· Presence of excessive terminal hair in androgen-dependent sites.
· Presence of acne.
· Presence of androgenetic alopecia.
· Biochemical evidence of Hyperandrogenism.
· Elevated serum concentrations of total or free testosterone.
· Elevated concentrations of dehydroepiandrosterone sulfate (DHEAS).
3. Polycystic Ovarian Morphology (PCOM)
· Presence of ≥12 follicles with a diameter of 2-9 mm in each ovary.
· Ovarian volume >10 ml.
EXCLUSION OF OTHER DISORDERS:
As PCOS is a "diagnosis of exclusion," it is important to rule out other disorders that may have similar clinical features:
· Congenital Adrenal Hyperplasia.
· Cushing Syndrome.
· Hyperprolactinemia.
· Thyroid Disorders.
· Androgen-producing tumors.
LABORATORY EVALUATION:
While not definitive, laboratory tests support the diagnosis and rule out other disorders.
Hormonal Investigations
· While not definitive, these tests support the diagnosis and rule out other disorders.
· Total and free testosterone levels.
· Elevated LH: FSH ratio, typically more than 2:1.
· DHEAS (to rule out hyperandrogenic states due to the adrenal gland).
· Serum prolactin.
· Thyroid-stimulating hormone (TSH).
METABOLIC ASSESSMENT
As PCOS is closely linked to the "metabolic syndrome," the patient should be screened for:
· Fasting blood glucose and/or oral glucose tolerance test.
· HbA1c.
· Lipid profile.
IMAGING STUDIES
· Pelvic Ultrasound.
It is recommended to use transvaginal ultrasound, but transabdominal ultrasound may be used in the unmarried/adolescent population.
Findings:
· Enlarged ovaries.
· Multiple small follicles.
· Increased stroma echogenicity.
CLINICAL EVALUATION
· A thorough clinical evaluation is necessary.
· Menstrual history.
· Onset of irregularities.
· Androgen excess.
· Hirsutism scoring.
· Acne.
· Alopecia.
· Body mass index.
· Waist circumference.
· Insulin resistance.
TREATMENT OF PCOS
Treatment of PCOS is symptom-oriented and patient-specific and includes the following:
1. LIFESTYLE MODIFICATION
This is the first line of treatment for all patients with PCOS and includes the following:
· Weight loss of 5-10%.
· Exercise and dietary habits.
2. MENSTRUAL IRREGULARITY
Treatment for menstrual irregularity includes the following:
· Combined Oral Contraceptive Pills (COCP) for regularizing menstrual cycles.
· Prevention of endometrial hyperplasia with COCP.
3. HYPERANDROGENISM (HIRSUTISM AND ACNE)
Treatment for hyperandrogenism includes the following:
· Combined Oral Contraceptive Pills (COCP) for hirsutism and acne.
· Anti-androgen therapy with Spironolactone.
· Cosmetic therapy for hirsutism with Laser and Waxing.
4. INSULIN RESISTANCE
Treatment for insulin resistance includes the following:
· Metformin for improving insulin sensitivity.
· Assistance with ovulation and regularizing menstrual cycles.
5. INFERTILITY TREATMENT
· First-line ovulation induction: Letrozole.
· Alternative: Clomiphene Citrate.
· Advanced treatment options: Gonadotropins or IVF.
6. LONG-TERM RISK MANAGEMENT
· Diabetes, hypertension, and lipid disorders.
· Prevention of cardiovascular complications.
LIFESTYLE MANAGEMENT OF PCOS
Lifestyle modifications are the first-line and most important treatment in managing PCOS, especially in overweight and obese women. Lifestyle modifications have positive effects on both fertility and metabolic problems in women with PCOS.
1. WEIGHT MANAGEMENT
· Weight loss of 5-10% has significant benefits in ovulation and menstrual cycles.
· Weight loss reduces insulin resistance and androgen levels.
· Even a small weight loss has clinical significance.
2. DIETARY MODIFICATIONS
Healthy eating habits include a diet with a low glycemic index
Increase food intake of:
· Whole grains.
· Fruits and vegetables.
· Proteins.
Decrease food intake of:
· Refined sugars.
· Refined carbohydrates.
· Saturated fats.
Regular meals have a positive effect on metabolism.
3. PHYSICAL ACTIVITY
At least 150 minutes/week of moderate physical activity
A combination of:
· Aerobic activities (walking, jogging, cycling).
· Resistance training (increases insulin sensitivity).
4. BEHAVIORAL INTERVENTIONS
· Goal setting and self-monitoring.
· Stress management techniques (yoga, meditation).
· Adequate sleep (7 to 8 hours/night).
· No smoking/alcohol.
5. BENEFITS OF LIFESTYLE MODIFICATION
· Restoration of ovulation.
· Improved menstrual cycles.
· Decreased symptoms of hirsutism and acne.
· Decreased risk of type 2 diabetes and cardiovascular disease.
RECENT ADVANCES IN PCOS TREATMENT
Recent advances in PCOS treatment include more emphasis on personalization, combination therapy, and metabolic therapy.
1. UPDATED GUIDELINES (2023)
The International Evidence-Based PCOS Guideline 2023 recommends the following for PCOS treatment:
· Lifestyle + Individualized Therapy.
· Letrozole as a first-line treatment for infertility.
· Screening and treatment of metabolic risks .
· ASRM.
2. IMPROVED OVULATION INDUCTION THERAPY
· Letrozole as a first-line treatment for ovulation induction.
· Recent meta-analyses demonstrate that Letrozole has higher rates of ovulation and pregnancy compared to clomiphene .
· Combination Therapy.
· Letrozole + Metformin may improve treatment outcomes .
3. NEW METABOLIC THERAPY FOR PCOS
GLP-1 Receptor Agonists (Emerging Therapy)
Examples: liraglutide, semaglutide
Benefits:
· Significant weight loss.
· Improved insulin sensitivity.
· SGLT-2 & DPP-4 Inhibitors.
Show promise in improving:
· Glucose metabolism.
· Hormonal imbalance.
4. COMBINATION THERAPY APPROACH
Modern research supports multi-drug strategies:
· Metformin + letrozole.
· Metformin + GLP-1 agonists.
These improve:
· Ovulation.
· Pregnancy rates.
· Metabolic profile.
5. PERSONALIZED/ PHENOTYPE-BASED TREATMENT
Treatment is tailored based on:
· Obesity vs lean PCOS.
· Fertility desire.
· Metabolic risk.
· Metformin shows different effectiveness depending on BMI .
6. EXPERIMENTAL & FUTURE THERAPIES
· Inositols (myo-inositol, D-chiro-inositol).
· Antioxidants (e.g., coenzyme Q10, thymoquinone).
· Gut microbiome-targeted therapies.
· Ongoing clinical trials exploring newer drugs.
COMPLICATIONS
· Reproductive: Infertility, menstrual irregularities, pregnancy risks ( gestational diabetes, pre eclampsia, miscarriage).
· Metabolic : Type 2 diabetes, Metabolic syndrome, cardiovascular diseases.
· Endocrine/ Oncologic: Endometrial hyperplasia and cancer.
· Psychological: Depression, anxiety, body image distress.
· Other: Sleep disorders, non- alcoholic fatty liver disease.
Note: PCOS is a multisystem disorder; early recognition and management are crucial to prevent long-term consequences.
DISCUSSION
Polycystic Ovary Syndrome (PCOS) – A prevalent endocrine disorder in women of reproductive age in India. Prevalence varies widely depending on the diagnostic criteria, population characteristics, and regions. Overall prevalence ranges from 3.7% to 22.5%. When considering NIH, Rotterdam, and AES diagnostic criteria, the pooled prevalence was found to be 11%. When considering the Rotterdam criteria, a higher prevalence was noted compared to NIH. NIH diagnostic criteria tend to report a lower prevalence compared to others. Variations in PCOS Prevalence – There are regional variations in PCOS. Urban populations tend to have a higher prevalence compared to rural populations. This may be due to lifestyle factors, obesity, and healthcare access. For example, studies conducted in Mumbai found a prevalence rate of 22.5%. Similarly, studies conducted in Delhi NCR found a prevalence rate of 17.4% in women aged 18-25. On the other hand, studies conducted in rural populations such as Lucknow and Chennai found a much lower prevalence rate ranging from 3.7% to 6%. Women in Andhra Pradesh belonging to a college-going age group were found to have a 9% prevalence rate. The factors affecting this variability include urban/rural settings, age group, methodology adopted for the study (clinical evaluation/symptoms), and criteria adopted for the diagnosis. Comparatively, the global prevalence of PCOS has been estimated to be in the range of 4-10%. Hence, the prevalence in India can be considered to fall within this range or slightly higher, especially in urban settings. Despite the high prevalence of PCOS, the epidemiology of PCOS in India has been affected by studies being conducted on a small scale, criteria adopted for the diagnosis being variable, and absence of large-scale studies.
LIFESTYLE MODIFICATIONS:
· Balanced dietary habits: Whole grains, lean protein sources, and low refined carbohydrates.
· Regular physical activity: At least 150 minutes per week.
· Weight Management: Even a 5-10% reduction in weight helps alleviate symptoms.
· Stress Management: Yoga, Meditation, Mindfulness.
MEDICAL MANAGEMENT( With physician concern):
· Hormonal Therapy: Use of oral contraceptives for menstrual regulation and hirsutism/ acne.
· Metformin: Use for insulin resistance.
· Fertility Therapy: Use of clomiphene and letrozole if pregnancy is desired .
SCREENING AND MONITORING:
· Regular evaluation of glucose, lipid profile, and blood pressure.
· Evaluation of reproductive health and endometrial status.
· Evaluation for metabolic and Cardiovascular risks.
PATIENT EDUCATION:
· Educating the patient about the symptoms, complications, and lifestyle.
· Encouraging patient compliance with treatment.
PUBLIC HEALTH MEASURES:
· Early detection in young girls and women.
· Public awareness campaigns for the prevention and recognition of PCOS.
CONCLUSION
Polycystic ovary syndrome (PCOS) Is a complex and heterogenous disorder with significant Reproductive, metabolic, and psychological consequences. Variations in clinical presentation and diagnostic criteria often contribute to delayed diagnosis and inconsistent management. Given its long-term health implications, including increased risk of metabolic and Cardiovascular diseases, PCOS requires a comprehensive and sustained approach to care . Emphasis on early screening , individualized management, and lifestyle modification is essential to improve outcomes. Furthermore, enhancing awareness, standardizing diagnostic approaches, and adopting multidisciplinary care strategies or crucial steps toward reducing the overall burden of PCOS and improving the quality of life among affected women.
REFERENCES
1. Wenwen Zhao, Jiayi Zhou, Yanhua Song, et Al. Polycystic ovary Syndrome Revisited: Novel Insights And Updates. Int J Med Sci. Jan,2026; 23(1). P: 271-282. https://doi.org/10.7150/ijms.119968
2. Anukrati Shukla, Lorena I. Rasquin, Catherine Anastaspoulou. Polycystic Ovarian Syndrome. In: StatPearls. Jul,2025. PMID: 29083730.
3. Ricardo Azziz, Enrico Carmina, et Al. Polycystic ovary syndrome. Nat Rev Dis Primers. Aug, 2016; 2. P: 16057. https://doi.org/10.1038/nrdp.2016.57
4. Hosna Mohammad Sadeghi, Ida Adeli, et Al. Polycystic ovary Syndrome: A Comprehensive Review Of Pathogenesis, Management, and Drug Repurposing. Int J Mol. Jan, 2022; 23(2). P: 583. https://doi.org/10.3390/ijms23020583
5. Adriana Catharina Helena Neven, Joop Laven, et Al. A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines. Semin Reprod Med. Jan,2018;36(1). P: 5-12. https://doi.org/10.1055/s-0038-1668085
6. Dual fahs, Dima Salloum, et Al. Polycystic Ovary Syndrome: Pathophysiology and Controversies in Diagnosis. Diagnostics( Basel). Apr,2023; 13(9). P: 1559. https://doi.org/10.3390/diagnostics13091559
7. Elizabeth Housman, Rachel V Reynolds. Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations. J Am Acad Dermatol. Nov,2014; 71(5). P: 847. https://doi.org/10.1016/j.jaad.2014.05.007
8. Heloise Helena Gonçalves de Moura, Dailana Louvain Marinho Costa, et Al. Polycystic Ovary Syndrome: A dermatologic approach. An Bras Dermatol. Jan,2011; 86(1). P: 111-9. https://doi.org/10.1590/s0365-05962011000100015
9. Farrah L Saleh, Hava Starkman, Allison Furness, et Al. Polycystic Ovary Syndrome in Adolescents. Obstetric Gynecol Clin North Am. Dec, 2024; 51(4). P: 679-693. https://doi.org/10.1016/j.ogc.2024.08.005
10. Daria Lizneva, Larisa Suturina, et Al. Criteria,Prevalence, and phenotype of Polycystic ovary syndrome. Fertil Steril. Jul,2016; 106(1). P: 6-15. PMID: 27233760.
11. Jim parker, Michael Kunicki. Editorial: Epigenetics of Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). Sep,2023; 14. P: 1284351. https://doi.org/10.3389/fendo.2023.1284351
12. Carla Pelusi, Renato Pasquali. Polycystic Ovary Syndrome in Adolescents. Treat Endocrinol. Aug,2012; 2. P: 215-230. https://doi.org/10.2165/00024677-200302040-00001
13. Ling-kun Yang, Wan-Jing MA, Xiao Wang, et Al. Apoptosis in polycystic ovary syndrome: Mechanisms and therapeutic implications. Life Sci. Feb,2025;363. P: 123394. https://doi.org/10.1016/j.lfs.2025.123394
14. Erin K Barthelmess, Rajesh K Naz. Polycystic Ovary Syndrome: Current status and Future Perspective. Front Biosci. Jan,2014; 6(1). P: 104-119. https://doi.org/10.2741/E695
15. Nicolás Omar Francone, Tia Ramirez, Christiana E Boots. Contemporary Management of the Patient With Polycystic Ovary Syndrome. Obstet Gynecol Clin North Am. Dec,2023; 50(4). P: 695-705. https://doi.org/10.1016/j.ogc.2023.08.003
16. Veronique Viardot – Foucault. Enhancing the Accuracy of Polycystic Ovary Syndrome Diagnosis. Ann Acad Med Singap. Dec,2023; 52(12). P: 647-648. https://doi.org/10.47102/annals-acadmedsg.2023397